Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
// Emily R. Theisen 1,* , Kathleen I. Pishas 1,2,* , Ranajeet S. Saund 1,* and Stephen L. Lessnick 1,3 1 Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA 2 Cancer Therapeutics Laboratory, Centre for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia 3 Division of Pediatric Hematology/Oncology/Bone Marrow Transplant at The Ohio State University, Columbus, Ohio, USA * These authors have contributed equally to this work and should be considered as co-first authors Correspondence to: Stephen L. Lessnick, email: // Keywords : Ewing sarcoma, LSD1, EWS-FLI, epigenetics, methylation Received : September 23, 2015 Accepted : January 23, 2016 Published : February 02, 2016 Abstract Ewing sarcoma is an aggressive primary pediatric bone tumor, often diagnosed in adolescents and young adults. A pathognomonic reciprocal chromosomal translocation results in a fusion gene coding for a protein which derives its N-terminus from a FUS/EWS/TAF15 (FET) protein family member, commonly EWS, and C-terminus containing the DNA-binding domain of an ETS transcription factor, commonly FLI1. Nearly 85% of cases express the EWS-FLI protein which functions as a transcription factor and drives oncogenesis. As the primary genomic lesion and a protein which is not expressed in normal cells, disrupting EWS-FLI function is an attractive therapeutic strategy for Ewing sarcoma. However, transcription factors are notoriously difficult targets for the development of small molecules. Improved understanding of the oncogenic mechanisms employed by EWS-FLI to hijack normal cellular programming has uncovered potential novel approaches to pharmacologically block EWS-FLI function. In this review we examine targeting the chromatin regulatory enzymes recruited to conspire in oncogenesis with a focus on the histone lysine specific demethylase 1 (LSD1). LSD1 inhibitors are being aggressively investigated in acute myeloid leukemia and the results of early clinical trials will help inform the future use of LSD1 inhibitors in sarcoma. High LSD1 expression is observed in Ewing sarcoma patient samples and mechanistic and preclinical data suggest LSD1 inhibition globally disrupts the function of EWS-ETS proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241 · cited 1×
“Methylation of histone H3 at lysine 4 (H3K4) and lysine 9 (H3K9) is linked to transcriptional activity at nearby genes [73].”
BackgroundGene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 2×
“While the histogenesis of Ewing sarcoma remains enigmatic, 85% of cases are defined by the t(11;22)(q24;q12) chromosomal translocation, resulting in a pathognomonic chimeric fusion gene, EWSR1-FLI1, which encodes the EWS-FLI protein [3].”
BackgroundShilatifard, A. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051710-134100 · Cited by 1,091 · cited 1×
“The methylation state of H3K4 is established through dynamic and coordinated activities of histone lysine methyltransferases, such as Set1/COMPASS family proteins, and histone lysine demethylases, such as FADdependent LSD1 and the JmjC domain containing JARID1 family [43, 75-77].”
BackgroundSchenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672 · cited 1×
“LSD1 is overexpressed in both solid and nonsolid tumors such as breast, lung, colon, prostate, gastric cancers and acute myeloid leukemia (AML), playing significant roles in cell proliferation, cell migration and metastasis [59, 62, 67, 69, 103-106].”
BackgroundFunctional annotation of native enhancers with a Cas9–histone demethylase fusion
Kearns, N. A., Pham, H., Tabak, B., Genga, R. M., Silverstein, N. J., Garber, M., & Maehr, R. (2015) · Nature Methods · doi:10.1038/nmeth.3325 · Cited by 656 · cited 1×
“However, LSD1 plays an important role in enhancer biology in embryonic stem cells (ESCs) and is required to repress the enhancers of pluripotency regulators during differentiation [94, 149, 150].”
BackgroundGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints
Ciccone, D. N., Su, H., Hevi, S., Gay, F., Lei, H., Bajko, J., Xu, G., Li, E., & Chen, T. (2009) · Nature · doi:10.1038/nature08315 · Cited by 514
May, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., & Denny, C. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7393 · Cited by 497
Self-citationHayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489 · cited 3×
“Owing to its high expression in several solid malignancies including breast [59-61], colorectal [62, 63], lung [62, 64], ovarian cancer [65], undifferentiated neuroblastoma [66], prostate carcinoma [67, 68], urothelial carcinoma [62], and sarcomas (Ewing, chondrosarcoma, osteosarcoma, rhabdomyosarcoma, and synovial) […”
BackgroundHistone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications
Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G., & Shiekhattar, R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.004 · Cited by 438
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes
Yang, J., Huang, J., Dasgupta, M., Sears, N., Miyagi, M., Wang, B., Chance, M. R., Chen, X., Du, Y., Wang, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016147107 · Cited by 340 · cited 1×
“In addition, LSD1 is reported to demethylate modified lysines on a myriad of non-histone proteins such as DNMT1 (residue K1096) [44], E2F1 (K185 residue) [45], MYPT1 (residue K442) [46], p53 (K370 residue) [47] and STAT3 (K140 residue) [48].”
Microsatellites as EWS/FLI response elements in Ewing's sarcoma
Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801073105 · Cited by 297 · cited 2×
“2, CAV1, GSTM4, and NR0B1 are regulated through EWS-FLI activity at nearby microsatellites, though none are currently candidates for therapeutic development [26, 30, 140-142].”
BackgroundSelf-citationFiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N. (2014) · Leukemia · doi:10.1038/leu.2014.119 · Cited by 284
Guillon, N., Tirode, F., Boeva, V., Zynovyev, A., Barillot, E., & Delattre, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004932 · Cited by 218 · cited 2×
“2, CAV1, GSTM4, and NR0B1 are regulated through EWS-FLI activity at nearby microsatellites, though none are currently candidates for therapeutic development [26, 30, 140-142].”
BackgroundSprüssel, A., Schulte, J. H., Weber, S., Necke, M., Händschke, K., Thor, T., Pajtler, K. W., Schramm, A., König, K., Diehl, L., et al. (2012) · Leukemia · doi:10.1038/leu.2012.157 · Cited by 203
Luo, W., Gangwal, K., Sankar, S., Boucher, K. M., Thomas, D., & Lessnick, S. L. (2009) · Oncogene · doi:10.1038/onc.2009.262 · Cited by 93 · cited 1×
“2, CAV1, GSTM4, and NR0B1 are regulated through EWS-FLI activity at nearby microsatellites, though none are currently candidates for therapeutic development [26, 30, 140-142].”
BackgroundSelf-citationEmergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma
Gangwal, K., Close, D., Enriquez, C. A., Hill, C. P., & Lessnick, S. L. (2010) · Genes & Cancer · doi:10.1177/1947601910361495 · Cited by 67 · cited 2×
“While several ETS-family members can bind GGAA repetitive elements in vitro, only EWS-FLI is able to both bind and activate transcription at nearby genes [139].”
BackgroundSelf-citation
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease
Li, P., Wu, Y., Hamlett, E. D., Goodwin, A. J., Halushka, P. V., Carroll, S. L., Liu, M., & Fan, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.023 · Cited by 33
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Metadata
- Authors
- Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 14
- Pages
- 17616-17630
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2296729394
- Cited by
- 70
- References
- 18
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.